INMED Pharmaceuticals Inc. (INM): ANSOFF Matrix Analysis [Jan-2025 Mis à jour]

Dans le paysage dynamique de l'innovation pharmaceutique, Inmed Pharmaceuticals Inc. apparaît comme une force pionnière, naviguant stratégiquement dans le monde complexe des thérapies à base de cannabinoïdes. En fabriquant méticuleusement une matrice ANSOff complète, la société dévoile une feuille de route audacieuse qui couvre la pénétration du marché, le développement, l'innovation des produits et la diversification stratégique - procelant pour révolutionner les soins de santé grâce à des technologies de cannabinoïdes de pointe. Plongez dans cette exploration de l'approche visionnaire d'InMed, où la précision scientifique rencontre un potentiel transformateur.

INMED Pharmaceuticals Inc. (INM) - Matrice Ansoff: pénétration du marché

Développez la visibilité des essais cliniques et le recrutement des patients

INMED Pharmaceuticals a mené 2 essais cliniques actifs en 2022, en se concentrant sur les programmes thérapeutiques à base de cannabinoïdes. Les données de recrutement des patients ont montré 47 participants inscrits à l'épidermolyse Bullosa et des études de glaucome.

Augmenter les efforts de marketing pour les professionnels de la santé

L'allocation du budget marketing pour 2022 était de 1,2 million de dollars, ciblant les conférences médicales spécialisées et les réseaux professionnels.

• Assisté à 7 conférences médicales internationales
• Conduit 12 webinaires ciblés
• Distribué 5 000 paquets d'information professionnels

Optimiser les processus de fabrication

Les initiatives de réduction des coûts de fabrication ont obtenu une amélioration de l'efficacité de la production de 18% en 2022.

Renforcer les partenariats stratégiques

Établi des partenariats avec 3 institutions de recherche en 2022.

• Collaboration de recherche de l'Université de la Colombie-Britannique
• Programme de recherche sur les cannabinoïdes de l'Université de Stanford
• Partenariat d'étude clinique de l'Université métropolitaine de Toronto

Investissement total de partenariat de recherche: 850 000 $ en 2022.

INMED Pharmaceuticals Inc. (INM) - Matrice Ansoff: développement du marché

Cibler les marchés internationaux avec des voies réglementaires établies pour les thérapies à base de cannabinoïdes

Inmed Pharmaceuticals a identifié les principaux marchés internationaux avec des cadres réglementaires progressifs de cannabinoïdes:

Explorer l'expansion des marchés émergents

Marchés émergents potentiels avec des réglementations en évolution du cannabis:

• Allemagne: Marché du cannabis médical d'une valeur de 1,5 milliard de dollars d'ici 2025
• Israël: 300 millions de dollars potentiel du marché du cannabis médical
• Thaïlande: premier pays asiatique avec une législation complète sur le cannabis médical

Développer des collaborations stratégiques

Partenariats actuels de distribution pharmaceutique:

Études de marché complètes

Cibler les segments de soins de santé avec un potentiel de marché important:

• Dermatologie: 23,6 milliards de dollars sur le marché mondial d'ici 2027
• Ophtalmologie: potentiel de marché de 62,4 milliards de dollars
• Gestion de la douleur: 87,2 milliards de dollars sur le marché mondial d'ici 2026

INMED Pharmaceuticals Inc. (INM) - Matrice Ansoff: développement de produits

Advance Research Pipeline pour les troubles cutanés rares et les conditions neurologiques

INMED Pharmaceuticals s'est concentré sur le développement de thérapies à base de cannabinoïdes pour des maladies rares. Au quatrième trimestre 2022, la société comptait 3 principaux candidats au médicament dans son pipeline de recherche.

Développer de nouveaux mécanismes d'administration de médicaments

INMED a investi 2,3 millions de dollars dans le développement de technologies propriétaires d'administration de médicaments en 2022.

• Recherche de formulation de cannabinoïdes topique
• Systèmes de livraison transdermiques avancés
• Plateformes de livraison de médicaments neurologiques ciblés

Investissez dans des plateformes de recherche avancées

Dépenses de recherche et développement pour 2022: 4,7 millions de dollars.

Améliorer le portefeuille de propriété intellectuelle

En décembre 2022, INMED détient 12 demandes de brevet actives dans le monde.

• 6 brevets dans les mécanismes de livraison des cannabinoïdes
• 4 brevets dans des applications thérapeutiques de maladies rares
• 2 brevets dans de nouvelles techniques de formulation de médicament

INMED Pharmaceuticals Inc. (INM) - Matrice Ansoff: diversification

Applications potentielles des technologies cannabinoïdes dans les secteurs de la santé adjacents

INMED Pharmaceuticals a déclaré 3,2 millions de dollars en frais de recherche et développement pour le quatrième trimestre 2022. La plate-forme de technologie cannabinoïde de la société se concentre sur les applications de dermatologie et de neurologie.

Opportunités d'investissement et d'acquisition stratégiques

La position de trésorerie d'Inmed était de 11,6 millions de dollars au 31 décembre 2022, permettant aux investissements potentiels du domaine de la biotechnologie.

• Budget d'acquisition de la biotechnologie: environ 5 à 7 millions de dollars
• Secteurs cibles: thérapeutiques de maladies rares
• Critères d'investissement: entreprises de scène préclinique

Initiatives de recherche potentielle de spin-off

Opportunités de licence technologique

Le portefeuille de brevets d'Inmed comprend 12 brevets accordés dans plusieurs juridictions.

• Revenus de licence potentielle: 2 à 4 millions de dollars par an
• Sociétés cibles: les 20 meilleures entreprises pharmaceutiques
• Focus sur les licences: technologies thérapeutiques à base de cannabinoïdes

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Market Penetration

The BayMedica commercial segment realized sales of $4.9M for the fiscal year ended June 30, 2025. This represented an increase of $0.34M, or 8%, compared to the fiscal year ended June 30, 2024.

For the three months ended March 31, 2025, BayMedica generated revenues of $1.26 million, matching the 8% growth rate seen for the full fiscal year 2025 period.

The broader market context for minor cannabinoid-infused edibles showed a 47% year-over-year growth in 2023, totaling $391 million in sales across ten regulated states.

The company's cash position as of June 30, 2025, was $11.1M, which supports funding planned operating expenses into the fourth quarter of calendar year 2026, depending on BayMedica revenues.

The following table summarizes the recent financial performance of the BayMedica commercial segment to frame the market penetration goals:

Actions to drive sales beyond the 8% fiscal 2025 growth rate include specific commercial strategies:

• Offer aggressive volume-based pricing to secure larger B2B supply contracts.
• Expand direct sales force coverage to capture more US health and wellness ingredient customers.
• Launch targeted digital campaigns emphasizing BayMedica's proprietary manufacturing quality.
• Target a revenue increase exceeding the $0.34M achieved between fiscal 2024 and fiscal 2025.

The proprietary manufacturing quality is supported by the development of a robust pilot-scale process for THCV production.

The company's stock price as of October 31, 2025, was $1.88, with a market capitalization of $4.48M.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Market Development

You're looking at how InMed Pharmaceuticals Inc. can take its existing rare cannabinoid ingredients and commercial structure, BayMedica, and push them into new geographic areas or new customer types. This is Market Development, and it needs cash to fund the expansion efforts.

Initiate regulatory filings to commercialize rare cannabinoids in key European Union markets.

The ability to fund the necessary regulatory steps for EU market entry is supported by the balance sheet as of the end of fiscal year 2025. InMed had $11.1 million in cash, cash equivalents, and short-term investments on June 30, 2025. This cash position is expected to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. The company recorded a net loss of $8.2 million for the year ended June 30, 2025.

Secure distribution partnerships to introduce BayMedica products into Asian functional food sectors.

The foundation for this expansion is the existing commercial business, BayMedica. For the year ended June 30, 2025, the BayMedica segment realized sales of $4.9 million. This represented an increase of $0.34 million, or 8%, compared to the year ended June 30, 2024. The business generates approximately 40 percent gross margins selling to the global health and wellness ingredient markets.

Target new B2B segments like high-end cosmeceuticals with existing rare cannabinoid ingredients.

Expanding into higher-value B2B segments like cosmeceuticals requires demonstrating the commercial viability of the current product line. The BayMedica Commercial segment reported an 8% increase in sales for the three months ended March 31, 2025, compared to the same period in 2024. However, the cost of sales for that segment increased by 23% for the same period, primarily due to an increase in sales of lower margin products. The overall annual revenue for fiscal year 2025 ending June 30, 2025, was $4.94 million, a 7.5% increase year-over-year.

Present BayMedica's commercial portfolio at international trade shows to find new global buyers.

Trade show presence is a direct sales and marketing cost that needs to be weighed against revenue generation. For the quarter ending September 30, 2025 (Q3 2025), revenue was reported at $1.12 million, which was up 11.43% year-over-year. The trailing twelve months ending September 30, 2025, showed total revenue of $4.80 million.

Here's a quick look at the key financial metrics supporting the commercial arm's ability to fund market development activities:

The performance of the BayMedica segment in fiscal 2025 shows a clear, albeit modest, growth trajectory:

• BayMedica segment sales growth for FY2025: 8%.
• Q1 2025 sales increase year-over-year: 8%.
• Q3 2025 sales year-over-year increase: 11.43%.
• Q3 2025 sales quarter-over-quarter change: down 14.1%.
• Increase in Cost of Sales for Q1 2025: 23%.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Product Development

You're looking at the core of InMed Pharmaceuticals Inc.'s (INM) growth engine-the product pipeline-which is squarely in the Product Development quadrant of the Ansoff Matrix. This means maximizing value from existing markets (pharmaceutical indications) by bringing new or improved products to them.

For INM-901, targeting Alzheimer's disease (AD), the focus has shifted to the final preclinical steps before human trials. As of November 2025, the company announced the successful completion of pharmacokinetic studies in large animal models for the oral formulation. This is a major step, as the data demonstrated robust bioavailability over a seven-day dosing period. The next required action is advancing into Investigational New Drug (IND)-enabling studies, which is being supported by preparing for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) and completing Chemistry, Manufacturing, and Controls (CMC) development to scale supply.

The financial underpinning for this work is clear. InMed reported a cash balance of \$11.1M as of June 30, 2025. A portion of this balance is earmarked for optimizing the oral formulation of INM-901, which is a critical activity preceding IND-enabling studies. This cash position is expected to support planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.

For INM-089, targeting dry Age-related Macular Degeneration (AMD), the preclinical work is being finalized to prepare for a first-in-human trial. The company selected an intravitreal (IVT) formulation for continued development in February 2025. This IVT formulation showed successful delivery in preclinical studies at doses up to 10 times the calculated safety margin relative to the therapeutic dose level. Furthermore, a series of dose-ranging in vivo studies were recently completed, with the resulting information guiding the selection of doses for pivotal preclinical toxicology studies, which are the next step toward an IND filing.

The development of INM-755 for Epidermolysis Bullosa (EB) is currently focused on securing external funding to move into Phase 3, as the Phase 2 trial is complete. The company is actively seeking strategic pharmaceutical partners to fund and advance this program.

Here is a snapshot of the key development activities and financial context:

The allocation of capital directly supports these product advancements. The investment into optimizing the oral formulation of INM-901 is a direct use of the company's liquidity.

• Cash balance as of June 30, 2025: \$11.1M.
• Expected cash runway into: Q4 2026.
• INM-901 optimization is a planned use of a portion of this cash.
• INM-901 preclinical work included a seven-day dosing study.

To be fair, the path from completing PK studies to starting IND-enabling studies requires rigorous documentation and regulatory alignment. Finance: finalize the budget allocation for INM-901 formulation optimization by next Tuesday.

InMed Pharmaceuticals Inc. (INM) - Ansoff Matrix: Diversification

Initiate a new drug discovery program targeting a novel, high-unmet-need oncology indication.

The current pharmaceutical focus includes INM-901 for Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration, both proprietary small molecule drug candidates. The cash position as of June 30, 2025, was $11.1M, with an expected runway into the fourth quarter of calendar year 2026. This cash level must support the advancement of existing programs while funding a new oncology initiative.

Acquire a complementary small-molecule platform outside of the current CB1/CB2 receptor focus.

InMed Pharmaceuticals Inc.'s existing pipeline is noted for targeting the CB1/CB2 receptors. Diversification here would mean adding a platform that operates outside this established mechanism. The fiscal year 2025 net loss was $8.2M, compared to $7.7M in the prior year. Any acquisition would need to be financed against this current burn rate and cash reserve.

Leverage the IntegraSyn manufacturing technology to produce non-cannabinoid, high-value Active Pharmaceutical Ingredients (APIs).

The IntegraSyn system was developed to produce pharmaceutical-grade, bio-identical cannabinoids, achieving a cannabinoid yield of 5 g/L. To pivot this technology to non-cannabinoid APIs would require retooling or proving the modularity of the process for different substrates. Research and development expenses for the year ended June 30, 2025, totaled $2.9M.

Establish a joint venture with a major biotech firm to co-develop a new therapeutic in a non-CNS/Ocular market.

Current pharmaceutical development is centered on CNS (Alzheimer's) and Ocular (AMD) indications. A joint venture outside these areas represents a significant market diversification. BayMedica, the commercial segment, realized sales of $4.9M for the year ended June 30, 2025, an increase of 8% year-over-year. This commercial revenue stream provides a financial base, though General and administrative expenses rose to $6.6M in FY2025 from $5.8M in FY2024.

Here's the quick math on recent financial performance:

The current pipeline focus areas and associated data points are:

• INM-901 targets Alzheimer's disease pathology.
• INM-089 demonstrated neuroprotection in dry Age-related Macular Degeneration.
• IntegraSyn achieved a cannabinoid yield of 5 g/L.
• Cash on hand as of June 30, 2025, was $11.1M.
• Market Capitalization as of May 2025 was $2.83M.